Design Therapeutics Statistics
Share Statistics
Design Therapeutics has 56.62M shares outstanding. The number of shares has increased by 1.13% in one year.
| Shares Outstanding | 56.62M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 31.41M |
| Failed to Deliver (FTD) Shares | 91 |
| FTD / Avg. Volume | 0.05% |
Short Selling Information
The latest short interest is 2.59M, so 4.57% of the outstanding shares have been sold short.
| Short Interest | 2.59M |
| Short % of Shares Out | 4.57% |
| Short % of Float | 8.25% |
| Short Ratio (days to cover) | 16.31 |
Valuation Ratios
The PE ratio is -2.22 and the forward PE ratio is -5.71.
| PE Ratio | -2.22 |
| Forward PE | -5.71 |
| PS Ratio | 0 |
| Forward PS | 6.5 |
| PB Ratio | 0.53 |
| P/FCF Ratio | -2.52 |
| PEG Ratio | n/a |
Enterprise Valuation
Design Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 29.58, with a Debt / Equity ratio of 0.01.
| Current Ratio | 29.58 |
| Quick Ratio | 29.58 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 0.83 |
| Cash Flow / Debt | -25.09 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.24% and return on capital (ROIC) is -27.85%.
| Return on Equity (ROE) | -0.24% |
| Return on Assets (ROA) | -0.23% |
| Return on Capital (ROIC) | -27.85% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.24M |
| Employee Count | 54 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -1 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 117.58% in the last 52 weeks. The beta is 1.83, so Design Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.83 |
| 52-Week Price Change | 117.58% |
| 50-Day Moving Average | 5.73 |
| 200-Day Moving Average | 4.53 |
| Relative Strength Index (RSI) | 50.82 |
| Average Volume (20 Days) | 169.85K |
Income Statement
In the last 12 months, Design Therapeutics had revenue of $0 and earned -$66.86M in profits. Earnings per share was $-1.19.
| Revenue | 0 |
| Gross Profit | -537.00K |
| Operating Income | -78.19M |
| Net Income | -66.86M |
| EBITDA | -66.33M |
| EBIT | - |
| Earnings Per Share (EPS) | -1.19 |
Balance Sheet
The company has $21.20M in cash and $3.05M in debt, giving a net cash position of $18.15M.
| Cash & Cash Equivalents | 21.20M |
| Total Debt | 3.05M |
| Net Cash | 18.15M |
| Retained Earnings | -177.63M |
| Total Assets | 261.63M |
| Working Capital | 249.81M |
Cash Flow
In the last 12 months, operating cash flow was -$58.56M and capital expenditures -$256.00K, giving a free cash flow of -$58.82M.
| Operating Cash Flow | -58.56M |
| Capital Expenditures | -256.00K |
| Free Cash Flow | -58.82M |
| FCF Per Share | -1.05 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
DSGN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -21.36% |
| FCF Yield | -18.65% |
Analyst Forecast
The average price target for DSGN is $5, which is -10.2% lower than the current price. The consensus rating is "Hold".
| Price Target | $5 |
| Price Target Difference | -10.2% |
| Analyst Consensus | Hold |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 24.4 |
| Piotroski F-Score | 4 |